Literature DB >> 17638861

Pten inactivation and the emergence of androgen-independent prostate cancer.

Michael M Shen1, Cory Abate-Shen.   

Abstract

Hormone refractory disease represents a late-stage and generally lethal event in prostate tumorigenesis. Analyses of mouse models have recently shown that the onset of hormone independence can be uncoupled from disease progression and is associated with activation of the phosphoinositide-3 kinase/Akt as well as Erk mitogen-activated protein kinase signaling pathways in the prostate epithelium, which act in part to counterbalance the inhibitory effects of androgen receptor signaling in the prostate stroma. These observations have potential implications for the treatment of patients with hormone refractory cancer and highlight the role of epithelial-stromal interactions for androgen independence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638861     DOI: 10.1158/0008-5472.CAN-07-1271

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

2.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

3.  Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Authors:  Maria Paola Paronetto; Manuela Cappellari; Roberta Busà; Simona Pedrotti; Roberta Vitali; Clay Comstock; Terry Hyslop; Karen E Knudsen; Claudio Sette
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

4.  AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.

Authors:  Ni Li; Wei Xue; Huairui Yuan; Baijun Dong; Yufeng Ding; Yongfeng Liu; Min Jiang; Shan Kan; Tongyu Sun; Jiale Ren; Qiang Pan; Xiang Li; Peiyuan Zhang; Guohong Hu; Yan Wang; Xiaoming Wang; Qintong Li; Jun Qin
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

5.  What controls PTEN and what it controls (in prostate cancer).

Authors:  Paramita M Ghosh
Journal:  Asian J Androl       Date:  2011-09-26       Impact factor: 3.285

6.  Regression of prostate cancer xenografts by RLIP76 depletion.

Authors:  Sharad S Singhal; Cherice Roth; Kathryn Leake; Jyotsana Singhal; Sushma Yadav; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2008-11-25       Impact factor: 5.858

7.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

8.  A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Authors:  Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Rebecca E Graff; Carlos L Morais; Jessica L Hicks; Kathryn M Wilson; Jennifer R Rider; Howard D Sesso; Michelangelo Fiorentino; Richard Flavin; Stephen Finn; Edward L Giovannucci; Massimo Loda; Meir J Stampfer; Angelo M De Marzo; Lorelei A Mucci; Tamara L Lotan
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

9.  Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.

Authors:  L Bonaccorsi; G Nesi; F Nuti; M Paglierani; C Krausz; L Masieri; S Serni; L Proietti-Pannunzi; Y Fang; S C Jhanwar; C Orlando; M Carini; G Forti; E Baldi; L Luzzatto
Journal:  J Endocrinol Invest       Date:  2009-05-05       Impact factor: 4.256

10.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.